This article provides a succinct review of women, HIV and pregnancy and is focused on the resource rich setting. Differences exist in management and access to interventions in the resource-poor setting but this will not be discussed in this manuscript.
Women with HIV who have access to lifelong combination antiretroviral therapy can expect to have a normal life expectancy. This combined with extremely low rates of perinatal transmission has resulted in many women now contemplating plans for parenthood. 
Management during pregnancy
The most important intervention to reduce perinatal HIV transmission is antiretroviral therapy for the mother 7 . It has been well established that combination therapy (rather than monotherapy)
is the most effective method for reducing maternal viral load, the most important predictor of perinatal transmission 8 . Recent data suggest that the earlier treatment is started, the lower the transmission rate 2 and if women enter pregnancy already on antiretrovirals then these should be continued 2 . Although safety data are still lacking on some of the newer antiretrovirals, the antiretroviral pregnancy registry provides reassuring data excluding teratogenicity for the majority of prescribed first line antiretrovirals 9 .
Under the Microscope
Historically, elective Caesarean section was recommended as an intervention to reduce perinatal transmission, although the data to support this were primarily before the advent of combination therapy with more recent analyses suggesting the risk of perinatal HIV transmission is comparable in women with an undetectable viral load 10, 11 . Today, vaginal birth is the recommended mode of delivery in women with an undetectable viral load (defined as either <50 copies/mL in guidelines from the United Kingdom to <1000 copies/ mL in guidelines from the United States) 12,13 unless there is an obstetric indication for a Caesarean section. Similarly, intrapartum zidovudine was previously prescribed routinely but is now reserved for women with a viral load at the time of delivery of >1000 copies/ mL 12, 13 . In addition to antiretrovirals for the mother, it is recommended that exposed neonates receive four weeks of monotherapy to further reduce the risk of HIV transmission.
Breastfeeding
When considering breastfeeding, the individual setting needs to be taken into account as guidelines regarding breastfeeding differ significantly between resource rich and resource poor settings. HIV has been found in breast milk and the only way to guarantee that HIV will not be transmitted after birth is for complete avoidance of breastfeeding. However when this is not possible or safe, recent studies have confirmed that with the use of antiretroviral therapy to either the mother or the infant for the duration of breastfeeding, rates of transmission can be reduced [14] [15] [16] . This has re-ignited debate regarding the support of women especially in resource rich settings who desire to breast feed despite the availability of safe, affordable, culturally appropriate alternatives. In this setting, although the recommendation remains avoidance of breastfeeding, it is becomingly increasingly recognised that if a well informed woman elects to breastfeed, knowing the potential risk associated with this, that she should be supported in this decision making process to maximize the likelihood of adherence to antiretroviral therapy rather than it be seen as a child protection issue 17 .
Management of the neonate
It is essential that infants born to HIV infected mothers are appro- Additionally, the burden of disease in indigenous populations is well recognised, and it is possible that fly-in fly-out workers could transmit infections 3 . In the United States and United Kingdom re-emergence is also underway, and congenital infections have been linked particularly to primary and secondary syphilis in females [4] [5] [6] .
Given the potential for further spread in Australia, ongoing vigilance is required.
Vertical transmission is highest in primary and secondary syphilis, continuing throughout pregnancy while the severity of outcomes decreases 7 . Adverse outcomes can include stillbirth or miscarriage, perinatal death, prematurity, low birthweight, and a series of early congenital manifestations (e.g. snuffles, hepatosplenomegaly, generalised lymphadenopathy, bony lesions) and late congenital manifestations (typically due to chronic granulomatous inflammation) 4, 8, 9 .
In Australia, universal screening for syphilis is recommended in pregnancy, with a treponemal-specific serological assay performed at the first antenatal visit, and repeat screening in high-risk populations should be considered at 28 weeks 10, 11 . Modalities available for diagnosing congenital syphilis in Australia include both treponemalspecific and non-treponemal specific serology, nucleic acid detection, direct fluorescent antibody testing, and histochemical staining (e.g. Warthin-Starry silver stain) ( Table 1) ; methods of historical
